Olatec Therapeutics LLC

www.olatec.com

Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma and breast cancers, among others. By selectively targeting NLRP3, the body’s first line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL 1 and IL 18. Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands.

Read more

Reach decision makers at Olatec Therapeutics LLC

Lusha Magic

Free credit every month!

Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma and breast cancers, among others. By selectively targeting NLRP3, the body’s first line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL 1 and IL 18. Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands.

Read more
icon

Country

icon

State

New York

icon

City (Headquarters)

New York City

icon

Employees

1-10

icon

Founded

2003

icon

Estimated Revenue

$1 to $1,000,000

icon

Social

  • icon
  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Vice President , Clinical Development Operations

    Email ****** @****.com
    Phone (***) ****-****
  • Vice President Operations

    Email ****** @****.com
    Phone (***) ****-****
  • Vice President Finance

    Email ****** @****.com
    Phone (***) ****-****
  • Co - Chief Science Officer

    Email ****** @****.com
    Phone (***) ****-****

Technologies

(14)

Reach decision makers at Olatec Therapeutics LLC

Free credits every month!

My account

Sign up now to uncover all the contact details